Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 229

1.

Examining patterns of multimorbidity, polypharmacy and risk of adverse drug reactions in chronic obstructive pulmonary disease: a cross-sectional UK Biobank study.

Hanlon P, Nicholl BI, Jani BD, McQueenie R, Lee D, Gallacher KI, Mair FS.

BMJ Open. 2018 Jan 14;8(1):e018404. doi: 10.1136/bmjopen-2017-018404.

2.

Adverse Drug Reactions in an Oncological Population: Prevalence, Predictability, and Preventability.

Lavan AH, O'Mahony D, Buckley M, O'Mahony D, Gallagher P.

Oncologist. 2019 Sep;24(9):e968-e977. doi: 10.1634/theoncologist.2018-0476. Epub 2019 Mar 4.

3.

Prevalence of polypharmacy in a Scottish primary care population.

Payne RA, Avery AJ, Duerden M, Saunders CL, Simpson CR, Abel GA.

Eur J Clin Pharmacol. 2014 May;70(5):575-81. doi: 10.1007/s00228-013-1639-9. Epub 2014 Feb 1.

PMID:
24487416
4.

Polypharmacy and specific comorbidities in university primary care settings.

Aubert CE, Streit S, Da Costa BR, Collet TH, Cornuz J, Gaspoz JM, Bauer D, Aujesky D, Rodondi N.

Eur J Intern Med. 2016 Nov;35:35-42. doi: 10.1016/j.ejim.2016.05.022. Epub 2016 Jun 9.

5.

Polypharmacy in palliative care-COPD and multimorbidity : A case report.

Rowhani M, Iglseder B.

Wien Med Wochenschr. 2018 May;168(7-8):177-183. doi: 10.1007/s10354-018-0633-3. Epub 2018 Apr 12.

PMID:
29651743
6.

A pharmacoepidemiologic study of community-dwelling, disabled older women: Factors associated with medication use.

Crentsil V, Ricks MO, Xue QL, Fried LP.

Am J Geriatr Pharmacother. 2010 Jun;8(3):215-24. doi: 10.1016/j.amjopharm.2010.06.003.

PMID:
20624611
7.

Multi-drug therapy in chronic condition multimorbidity: a systematic review.

Doos L, Roberts EO, Corp N, Kadam UT.

Fam Pract. 2014 Dec;31(6):654-63. doi: 10.1093/fampra/cmu056. Epub 2014 Sep 5. Review.

8.

Chronic condition comorbidity and multidrug therapy in general practice populations: a cross-sectional linkage study.

Roberts ER, Green D, Kadam UT.

BMJ Open. 2014 Jul 11;4(7):e005429. doi: 10.1136/bmjopen-2014-005429.

9.

Polypharmacy patterns: unravelling systematic associations between prescribed medications.

Calderón-Larrañaga A, Gimeno-Feliu LA, González-Rubio F, Poblador-Plou B, Lairla-San José M, Abad-Díez JM, Poncel-Falcó A, Prados-Torres A.

PLoS One. 2013 Dec 20;8(12):e84967. doi: 10.1371/journal.pone.0084967. eCollection 2013.

10.

Multimorbidity and COPD Medication Receipt Among Medicaid Beneficiaries With Newly Diagnosed COPD.

Ajmera M, Sambamoorthi U, Metzger A, Dwibedi N, Rust G, Tworek C.

Respir Care. 2015 Nov;60(11):1592-602. doi: 10.4187/respcare.03788. Epub 2015 Sep 1.

11.

Relationship between multimorbidity, demographic factors and mortality: findings from the UK Biobank cohort.

Jani BD, Hanlon P, Nicholl BI, McQueenie R, Gallacher KI, Lee D, Mair FS.

BMC Med. 2019 Apr 10;17(1):74. doi: 10.1186/s12916-019-1305-x.

12.

Adverse drug reactions and polypharmacy in the elderly in general practice.

Veehof LJ, Stewart RE, Meyboom-de Jong B, Haaijer-Ruskamp FM.

Eur J Clin Pharmacol. 1999 Sep;55(7):533-6.

PMID:
10501824
13.

Treatment burden, clinical outcomes, and comorbidities in COPD: an examination of the utility of medication regimen complexity index in COPD.

Negewo NA, Gibson PG, Wark PA, Simpson JL, McDonald VM.

Int J Chron Obstruct Pulmon Dis. 2017 Oct 6;12:2929-2942. doi: 10.2147/COPD.S136256. eCollection 2017.

14.

Multimorbidity, polypharmacy and primary prevention in community-dwelling adults in Quebec: a cross-sectional study.

Nguyen TN, Ngangue P, Haggerty J, Bouhali T, Fortin M.

Fam Pract. 2019 Nov 18;36(6):706-712. doi: 10.1093/fampra/cmz023.

PMID:
31104072
15.

Managing multimorbidity in primary care in patients with chronic respiratory conditions.

Morrison D, Agur K, Mercer S, Eiras A, González-Montalvo JI, Gruffydd-Jones K.

NPJ Prim Care Respir Med. 2016 Sep 15;26:16043. doi: 10.1038/npjpcrm.2016.43.

16.

Pill for this and a pill for that: A cross-sectional survey of use and understanding of medication among adults with multimorbidity.

Millar E, Gurney J, Stanley J, Stairmand J, Davies C, Semper K, Dowell A, Lawrenson R, Mangin D, Sarfati D.

Australas J Ageing. 2019 Jun;38(2):91-97. doi: 10.1111/ajag.12606. Epub 2018 Dec 16.

PMID:
30556358
17.

Determinants of polypharmacy and compliance with GOLD guidelines in patients with chronic obstructive pulmonary disease.

Franssen FM, Spruit MA, Wouters EF.

Int J Chron Obstruct Pulmon Dis. 2011;6:493-501. doi: 10.2147/COPD.S24443. Epub 2011 Sep 26.

18.

Chronic obstructive pulmonary disease and comorbidities: a large cross-sectional study in primary care.

Chetty U, McLean G, Morrison D, Agur K, Guthrie B, Mercer SW.

Br J Gen Pract. 2017 May;67(658):e321-e328. doi: 10.3399/bjgp17X690605.

19.

Multimorbidity in Māori and Pacific patients: cross-sectional study in a Dunedin general practice.

Stokes T, Azam M, Noble FD.

J Prim Health Care. 2018 Mar;10(1):39-43. doi: 10.1071/HC17046.

PMID:
30068450
20.

General practitioners' views on polypharmacy and its consequences for patient health care.

Köberlein J, Gottschall M, Czarnecki K, Thomas A, Bergmann A, Voigt K.

BMC Fam Pract. 2013 Aug 15;14:119. doi: 10.1186/1471-2296-14-119.

Supplemental Content

Support Center